1926 ± 760 Improved diast fx. Canaud 1998 (10) Retrospective 52 19/33 100% IV C/T, CM, BSM-22 Hospal, Lyon, Fr. SCUF, SCUF x 72 h, 35 pts with M wt loss 9.3 ± In 35 BP stability req. ↑ PlE ?SDUF SDUF 4-8 h/d oliguria (UO 5.0 Kg in 9 ± Surv. adj. of UF rates, ↓ < 500ml/d); 10.5 d; BUN from inotropes, IV saline from 33 ± 14 to ↑natriuresis 17 pts UO 30 to 55 mmol/d; 31 ±13 800-1500ml/d mg/dl and 24 sCr from improved both 417± 332 cardiac (CXR to 306 ± and Echo) and 189 fx.( 6 for 3 mmol/l ≤ mos, 18 for > 3 mos, 8 recurrent HF) 15 Partial resp. : improved cardiac fx. But progression to ESRD req. RRT; 13 Non-Resp died 1 mo ≤ For additional information, readers are referred to references (5,7,24,25), which are other studies investigating extracorporeal fluid using early ultrafiltration devices (data from these studies are not summarized in the table) Supplemental Table 3. Pilot Studies with Contemporary Ultrafiltration Systems Author/Y Type No. of Etiology of HF LVEF < NYHA Sx. & Symptoms Membrane/Pump UF Baseline /Post-Rx Duration of F/U Outcomes Pts. (Isch./NI) 40% of HF Removed BUN/sCr (mg/dL)
1926 ± 760 Improved diast fx. Canaud 1998 (10) Retrospective 52 19/33 100% IV ↑ C/T, CM, PlE BSM-22 Hospal, Lyon, Fr. SCUF, ?SDUF SCUF x 72 h, SDUF 4-8 h/d 35 pts with oliguria (UO < 500ml/d); 17 pts UO 800-1500ml/d M wt loss 9.3 ± 5.0 Kg in 9 ± 10.5 d; ↑natriuresis from 30 to 55 mmol/d; 24 improved both cardiac (CXR and Echo) and fx.( 6 for ≤ 3 mos, 18 for > 3 mos, 8 recurrent HF) 15 Partial resp. : improved cardiac fx. But progression to ESRD req. RRT; 13 Non-Resp died ≤ 1 mo In 35 Surv. ↓ BUN from 33 ± 14 to 31 ±13 mg/dl and sCr from 417± 332 to 306 ± 189 mmol/l BP stability req. adj. of UF rates, inotropes, IV saline For additional information, readers are referred to references (5,7,24,25), which are other studies investigating extracorporeal fluid using early ultrafiltration devices (data from these studies are not summarized in the table) Supplemental Table 3. Pilot Studies with Contemporary Ultrafiltration Systems Author/Y Type No. of Pts. Etiology of HF (Isch./NI) LVEF < 40% NYHA Sx. & Symptoms of HF Membrane/Pump UF Removed Baseline /Post-Rx BUN/sCr (mg/dL) Duration of F/U Outcomes
1-s2.0-S0735109717366974-mmc1.docx